Osaka's labs keep producing Nobel-level science. Companies are the harder problem - and Osaka is only just starting to solve it.
The purchase adds an established hypertension brand to the company's cardiovascular range.
The EAHP and EFPIA want all individual doses to carry a barcode, an addition they say will further reduce medication errors.
This follows the establishment of an invasive mosquito population in a region of Cyprus.
Aptar's ACT-101 is designed to intervene a step earlier than current CF modulators.
The laboratory is expected to open in 2027 and create new jobs in the region.
